Continuous glucose monitoring (CGM) has made it possible to assess the patterns and trends of blood glucose and the substantial variability in glucose excursions in people with type 1 diabetes, even in those who are well controlled ([@B1]). The benefits of this technology are most apparent with near-continuous wear of the sensors, in which knowledge gained in identifying glycemic patterns, such as with meals and exercise, is incorporated into the day-to-day management of the individual's diabetes. The latter has proven to be more difficult to accomplish in children than in adults. In the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group randomized controlled trial (JDRF CGM RCT), only adults had a reduction in mean HbA~1c~ ([@B2]). However, in both children and adults, use of CGM for ≥6 days/week was associated with an HbA~1c~ reduction ([@B3]). Other studies report a similar association between the amount of CGM use and HbA~1c~ levels ([@B4]--[@B8]).

The use of CGM has been less well studied in younger children with type 1 diabetes, a group in whom parents, by necessity, are responsible for diabetes management, and parental fear of hypoglycemia often prevents better glycemic control ([@B9]--[@B11]). Therefore, we designed an RCT to evaluate the efficacy, safety, and effect of CGM on quality of life in younger children (aged 4 to 9 years).

RESEARCH DESIGN AND METHODS {#s5}
===========================

The trial was conducted by the Diabetes Research in Children Network (DirecNet). The protocol was approved by the institutional review boards of the five participating sites. Written informed consent was obtained from the parents/guardians, and the child's assent was obtained when appropriate. The study is listed on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT00760526).

Study participants had a clinical diagnosis of type 1 diabetes and were using daily insulin therapy for at least 12 months. Eligibility criteria included age 4.0 to \<10.0 years, HbA~1c~ ≥7.0%, and basal-bolus therapy using either an insulin pump or at least three multiple daily injections (MDIs) of insulin for the prior 3 months with no plans to switch the insulin modality within the next 6 months. Exclusion criteria included *1*) diagnosis of diabetes prior to 6 months of age; *2*) use of a medication that could affect glycemic control, the performance of the CGM sensor, or completion of any aspect of the protocol; and *3*) use of CGM during the prior 6 months.

After enrollment, participants had a run-in period for a minimum of 6 weeks to optimize glycemic control prior to CGM use. During the run-in period, a blinded CGM device was then used for 2 to 4 weeks to familiarize the participant and parent with its use and to obtain CGM data as a baseline assessment of glycemic control. To be randomized, participants had to wear the CGM for a minimum of 7 of 14 days; have no severe skin reaction at the insertion site; have at least 96 h of CGM values, including at least 24 h during 10 [p.m.]{.smallcaps} to 6 [a.m.]{.smallcaps}; and have performed a minimum of three blood glucose meter measurements per day. Participants meeting these criteria were randomly assigned to either the CGM group or the usual care control group, using a permuted-blocks design stratified by clinical center.

Participants randomized to the CGM group were provided with an unblinded CGM device, sensors, and FreeStyle Flash (Abbott Diabetes Care, Inc., Alameda, CA) blood glucose meter and test strips. A FreeStyle Navigator (Abbott Diabetes Care, Inc.) was provided unless the participant was already using a Medtronic Paradigm insulin pump (Medtronic MiniMed, Inc., Northridge, CA), in which case a MiniMed MiniLink REAL-Time Transmitter (Medtronic MiniMed, Inc.) could be used. Parents were instructed on the use of the device and encouraged to use the sensor on a daily basis. They were instructed to continue testing with the home blood glucose meter ≥4 times each day and to verify the accuracy of the CGM glucose measurement with the home blood glucose meter before making management decisions. Participants in the control group were given a FreeStyle Flash blood glucose meter and test strips and asked to perform blood glucose monitoring at least four times daily.

Parents of participants in both the CGM and control groups were provided with detailed verbal and written instructions on how to use CGM and blood glucose meter data, respectively, to make real-time insulin dose adjustments and on using computer software to retrospectively review the glucose data to alter insulin dosing (if a computer was available at home for downloading). The insulin dose adjustment algorithms are available on the DirecNet public Web site (<http://direcnet.jaeb.org/Studies.aspx?RecID=162>). Target glucose values were 80--150 mg/dL before meals, \<200 mg/dL after meals, 100--150 mg/dL at bedtime, and 80--150 mg/dL overnight.

The number of scheduled contacts was identical for both treatment groups. Visits were conducted at 1, 4, 8, 13, 19, and 26 weeks (± 1 week) postrandomization, with one scheduled phone contact between each visit, to review glucose data and adjust diabetes management, as indicated. After the 13- and 26-week visits, the control group wore a blinded CGM device to collect a minimum of 96 h of glucose values overall, with at least 24 h overnight.

Bayer DCA (Tarrytown, NY) point-of-care devices were used for HbA~1c~ measurements at each visit with the exception of the 1-week visit. A blood sample was collected at baseline, 13 weeks, and 26 weeks for measurement of HbA~1c~ at the University of Minnesota using the Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer (Tosoh Medics, Foster City, CA) method ([@B12]). The parent completed the following questionnaires at baseline (prior to initiating use of the blinded CGM device) and at 26 weeks: Glucose Monitoring Survey ([@B13]), Pediatric Assessment In Diabetes Survey--Parent Version (PAID) ([@B14]), and Hypoglycemia Fear Survey ([@B15]--[@B17]). In addition, the CGM Satisfaction Scale ([@B13],[@B18]) was completed by the parent for those in the CGM group at 26 weeks. Severe hypoglycemia was defined as an event requiring assistance of another person, as a result of altered consciousness, to administer carbohydrate, glucagon, or other resuscitative actions. For those developmentally too young to independently recognize and treat hypoglycemia, hypoglycemia was considered severe if there were associated signs or symptoms of neuroglycopenia, including temporary impairment of cognition; incoherent, disoriented, and/or combative behavior; seizure; or coma.

Statistical methods {#s6}
-------------------

The primary outcome was a binary variable, defined as a decrease in HbA~1c~ of ≥0.5% from baseline to 26 weeks and no severe hypoglycemic events. A sample size of 140 was planned to have 90% power to detect an absolute difference in this outcome between treatment groups of 25%, assuming a control group rate of 10% (based on control group data from the JDRF CGM RCT) ([@B2]), an α-level of 0.05, and ≤7.5% losses to follow-up.

Analyses followed the intent-to-treat principle, with all participants analyzed in the group to which they were randomized regardless of actual sensor use. Treatment group comparisons of binary outcomes were performed with logistic regression models, adjusted for baseline HbA~1c~ level and clinical center. The comparisons of continuous outcomes, including HbA~1c~, questionnaire data, and CGM glucose data, were made using ANCOVA models adjusted for their corresponding baseline values and clinical center. There was one outlier for HbA~1c~ (changed from 10.5% at baseline to 7.9% at 26 weeks), and the results were similar using a rank transformation (data not shown). In addition, CGM glucose data were transformed using van der Waerden normal scores, and the comparisons were adjusted for baseline HbA~1c~ level and type of CGM device. The percentages of participants with at least one severe hypoglycemic event in the two treatment groups were compared using Fisher exact test, and the incidences were compared using a permutation test.

Among participants in the CGM group, change in the amount of CGM use over time was assessed using a repeated-measures regression model based on van der Waerden transformed scores. Spearman rank correlations between the amount of CGM use and age, baseline HbA~1c~, and change in HbA~1c~ were computed. Changes in HbA~1c~ from baseline in the participants who wore CGM ≥6 days/week vs. \<6 days/week were compared using least squares regression model adjusted for baseline HbA~1c~ level and clinical center.

Analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC). All *P* values are two-sided.

RESULTS {#s7}
=======

Between January 2009 and December 2010, the trial randomized 146 children aged 4.0--9.9 years (7.5 ± 1.7 years \[mean ± SD\]) who had a median duration of type 1 diabetes of 3.5 years (interquartile range 2.2--5.2). The majority of participants was non-Hispanic white and was using insulin pumps. Baseline characteristics were well balanced between the two treatment groups ([Table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics of the participants

![](204tbl1)

HbA~1c~ decreased by a mean of 0.2 ± 0.7% (measured with a DCA instrument) during the run-in phase. Mean HbA~1c~ at the time of randomization (measured by central laboratory) was 7.9 ± 0.8% in each treatment group. Total daily insulin dose averaged 0.8 ± 0.2 units/kg/day in both treatment groups at baseline and at 26 weeks.

The 26-week primary outcome visit was completed by 69 of 74 participants (93%) in the CGM group and 68 of 72 (94%) in the control group, with 5 and 4 participants in the two treatment groups, respectively, discontinuing study participation prior to completion of the 26-week visit ([Supplementary Fig. A1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1)). The overall completion rates for the six follow-up visits and the six protocol-specified phone calls were 93% and 94% in the CGM and control groups, respectively.

Among the 74 participants in the CGM group, 10 (14%) were provided with a Paradigm CGM device and 64 (86%) with a Navigator CGM device. No participants in the control group self-initiated CGM prior to completing the 26-week visit.

Glycemic control {#s8}
----------------

The primary outcome of a decrease from randomization to 26 weeks in HbA~1c~ ≥0.5% with no severe hypoglycemic events occurred in 13 of 69 (19%) participants in the CGM group and 19 of 68 (28%) in the control group (*P* = 0.17). Mean change in HbA~1c~ was similar between groups (−0.1 ± 0.6 in each group, *P* = 0.79) ([Supplementary Fig. A2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1)). Other HbA~1c~ outcomes at 26 weeks showed similar comparability between treatment groups ([Table 2](#T2){ref-type="table"}). Outcomes in subgroups based on age, sex, race/ethnicity, parent education level, insulin modality (pump vs. MDIs), baseline HbA~1c~, or BMI also did not differ between groups and are shown in [Supplementary Table A1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1).

###### 

Outcomes at 26 weeks\*
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Glycemic outcomes measured with CGM showed no significant differences between treatment groups (considering the multiple outcomes assessed) with respect to percent of values within, above, and below the target range ([Table 2](#T2){ref-type="table"} and [Supplementary Table A2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1)). Participants in both groups had glucose values \>250 mg/dL for \>20% of the day.

Hypoglycemia and other adverse events {#s9}
-------------------------------------

Three participants (4%, three total events) in the CGM group and five participants (7%, six total events) in the control group experienced at least one severe hypoglycemic event, with no significant differences comparing treatment groups (incidence rate = 8.6 and 17.6 per 100 person-years, respectively; *P* = 0.80) ([Table 2](#T2){ref-type="table"}). At 26 weeks, both groups had CGM glucose values ≤60 mg/dL for \<1% of the day. There were no cases of diabetic ketoacidosis and no serious adverse events attributable to the study interventions, including no serious skin reactions.

Frequency of sensor use in the CGM group {#s10}
----------------------------------------

A total of 63 (91%) of 69 participants who completed the 26-week visit were wearing a sensor on at least 1 day a week at the end of 26 weeks. The amount of CGM sensor wear decreased during the 26 weeks of the study (*P* \< 0.001) ([Fig. 1](#F1){ref-type="fig"}), with only 41% averaging at least 6 days/week of wear in month 6. The amount of sensor wear in month 6 did not vary with age overall (*r* = −0.07) and was not associated with baseline HbA~1c~ (*r* = −0.02).

![Sensor use during the 26 weeks of the trial. Each box represents the number of hours per week of CGM sensor glucose data averaged over 4 weeks. The top and bottom of the boxes represent the 75th and 25th percentiles, respectively; the horizontal line within each box represents the median; and the black dot represents the mean. For participants who dropped from the trial, sensor use was considered to be zero after the day of dropout. Data were considered missing when downloaded glucose data were not available for a 4-week period. \*Sensor download was unavailable due to device issue for one subject in 22--26 weeks.](204fig1){#F1}

There was no association between change in HbA~1c~ from baseline to 26 weeks and the overall amount of CGM sensor wear during the entire 26 weeks (Spearman *r~s~* = −0.09, *P* = 0.44) or during month 6 (Spearman *r~s~* = −0.11, *P* = 0.37). However, the 28 participants who wore a sensor ≥6 days/week during month 6 tended to have a slightly greater reduction in HbA~1c~ compared with the 41 participants who wore a sensor less frequently (mean change from baseline to 26 weeks −0.3 ± 0.7% vs. 0.0 ± 0.5%, *P* = 0.01; 25 vs. 15% with a reduction in HbA~1c~ ≥0.5% without a severe hypoglycemia event, *P* = 0.33). Among those wearing a sensor ≥6 days/week in month 6, the median percentage of glucose values in the target range of 71--180 mg/dL was 51%, with 38% \>200 mg/dL, 16% \>250 mg/dL, and 0.3% ≤60 mg/dL compared with 43, 44, 23, and 0.4%, respectively, in those wearing a sensor less frequently.

Quality of life assessments {#s11}
---------------------------

At 26 weeks, there were no significant differences between treatment groups on the Hypoglycemia Fear or the PAID questionnaire survey scores ([Table 2](#T2){ref-type="table"} and [Supplementary Tables A3 and A6](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1)). However, scores on the Blood Glucose Monitoring System Rating Scale were indicative of fewer problems/concerns perceived by the CGM group compared with the control group ([Table 2](#T2){ref-type="table"} and [Supplementary Table A5](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1)).

On the CGM Satisfaction Scale at 26 weeks ([Table 3](#T3){ref-type="table"} and [Supplementary Table A4](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1)), parents generally reported a high degree of satisfaction with CGM, with an average item score of 3.9 and 86% of scores ≥3.5 (on a 5-point Likert-type scale, with 3 being neutral). Mean item scores were more favorable than neutral (\>3.0) on all 43 items. Scores on the Benefits of CGM subscale tended to be slightly higher than scores on the Lack of Hassles of CGM subscale (mean 4.1 ± 0.4 vs. 3.9 ± 0.6, respectively). It is particularly noteworthy that \>90% of parents responded that use of CGM makes adjusting insulin easier, shows patterns in blood glucose not seen before, and makes them feel safer knowing that they will be warned about low blood glucose before it happens. No one responded that he or she would not recommend CGM for other children with type 1 diabetes.

###### 

CGM Satisfaction Scale scores\* at 26 weeks (*N* = 69)
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CONCLUSIONS {#s12}
===========

In this RCT in preschool- and school-aged children with type 1 diabetes, we found no benefit of wearing a CGM sensor on glycemic control after a 26-week follow-up period, despite high parental satisfaction with CGM. The incidence of severe hypoglycemia was low and comparable between the two groups, similar to published results in older children and adults in other trials ([@B1],[@B2],[@B4],[@B6],[@B8]). There were no other serious adverse events, including no serious skin issues.

In the CGM group, sensor wear decreased over the 26 weeks, with only 41% averaging at least 6 days/week of wear in month 6. The amount of sensor wear did not vary significantly with age or HbA~1c~ level. This decrease over time is similar to what was observed in the 8- to 14-year-olds in the JDRF CGM RCT ([@B3]). However, in the current trial, even when the CGM sensor was worn ≥6 days/week during the 6th month of the trial, improvement in HbA~1c~ was modest and less than the mean HbA~1c~ improvement seen in the 8- to 14-year-olds who used CGM regularly in the JDRF CGM RCT (0.3 vs. 0.8%).

Because parental responses on the Lack of Hassles of CGM subscale did not indicate major problems with the use of CGM, problems with the insertion and maintenance of a sensor do not appear to have been primary impediments to improving glycemic control in this age group. Accuracy of the CGM sensor was also not stated as a concern. It also seems unlikely that the lack of improvement was related to inadequate training and instructions on insulin dosing because the subjects were contacted and data reviewed on the same frequent schedule that was used in the JDRF CGM RCT, in which frequent CGM wear was associated with greater improvement in HbA~1c~. The parents of the study participants generally were well educated, representing a selected population interested in using CGM as part of their child's diabetes management. Therefore, it seems unlikely that parent education level or lack of motivation contributed to the lack of benefit on glycemic control.

Why then was parental report that CGM helped with management not reflected in better HbA~1c~ levels? Several factors may have played a role. The target blood glucose levels were those recommended by the American Diabetes Association to mitigate the risks of hypoglycemia in young children with type 1 diabetes ([@B19]); thus, it is possible that the insulin-adjusting algorithms that were used in this study may have contributed to the failure to substantially lower HbA~1c~ levels in our subjects by setting higher target levels to minimize hypoglycemia. We also speculate that avoidance of hypoglycemia might have been so important to the parents of these young children that they were reluctant to tighten glycemic control and increase the risk of hypoglycemia. Although responses on the CGM Satisfaction Scale indicated a strong perceived benefit of CGM in warning about hypoglycemia, no significant treatment group differences were found on the Hypoglycemia Fear Survey at 26 weeks. We conjecture that this apparent discordance may be explained by the fact that even though wearing a sensor provided parental reassurance and comfort on a daily basis (as measured on the CGM Satisfaction Scale), sensor wear might not alter an underlying deep-rooted fear of hypoglycemia (as measured on the Hypoglycemia Fear Survey). In fact, for some parents, it is possible that observing downward trends of the CGM glucose levels actually might have made them even less aggressive in trying to achieve tighter glycemic control because of their fear of hypoglycemia. At 26 weeks, the amount of time the glucose level was ≤60 mg/dL was extremely small (median 6 min/day), whereas glucose levels were high for a substantial portion of the day: \>200 mg/dL for ∼10 h/day (median) even when a sensor was being worn ≥6 days/week.

In summary, CGM in 4- to 9-year-olds did not improve glycemic control, despite a high degree of parental satisfaction with CGM. We postulate that this may be related to limited use of CGM glucose data in the day-to-day management of diabetes, target glucose levels that are too high, and a persistent, unremitting fear of hypoglycemia in the parents of these young children. Overcoming the barriers that prevent the integration of these glucose data into day-to-day management of pediatric diabetes remains a substantial challenge.

Supplementary Material
======================

###### Supplementary Data

Clinical trial reg. no. NCT00760526, [clinicaltrials.gov](clinicaltrials.gov).

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1746/-/DC1>.
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